title: Content of reticulocyte hemoglobin is a reliable tool for determining iron deficiency in dialysis patients.
abstract: BACKGROUND
  The evaluation of iron status in dialysis patients provides information essential to the planning of adequate recombinant human erythropoietin (rHuEPO) treatment. Iron status of the patients can be determined from the recently available measurement of content of reticulocyte hemoglobin (CHr).
  
  
  METHODS
  In this study, to clarify the accuracy of CHr in diagnosing iron deficiency in hemodialysis (HD) patients, we initially compared CHr with such conventional iron parameters as serum ferritin levels, transferrin saturation and serum soluble transferrin receptor levels. Secondly, we investigated the changes in CHr during iron supplementation for iron-deficient patients to determine whether this marker is a prospective and reliable indicator of iron sufficiency. The participants in this study were 149 hemodialysis (HD) patients and 53 age-matched healthy subjects. Iron deficiency was defined as having a TSAT of less than 20% and serum ferritin of less than 100 ng/ml. Conventional parameters of red blood cells and CHr were measured by an ADVIA120 autoanalyzer.
  
  
  RESULTS
  Mean CHr was 32.3 +/- 2.2 pg in the patients undergoing hemodialysis treatment. CHr significantly correlated with iron parameters in the dialysis patients. Logistic regression analysis was performed to determine the relationship between CHr and each outcome measure, and CHr was the significant multivariate predictor of iron deficiency. Iron supplements given to the patients with low CHr and hematocrit (Hct) significantly increased Hct, resulting in a decrease in the weekly dosage of rHuEPO.
  
  
  CONCLUSIONS
  CHr, measured simultaneously with Hct, is a sensitive and specific marker of iron status in dialysis patients.
authors.affiliation: Department of Medicine IV, Tokyo Women's Medical University, Tokyo, Japan. tsuchiya@kc.twmu.ac.jp
authors.forename: K
authors.initials: K
authors.lastname: Tsuchiya
authors.forename: H
authors.initials: H
authors.lastname: Okano
authors.forename: M
authors.initials: M
authors.lastname: Teramura
authors.forename: Y
authors.initials: Y
authors.lastname: Iwamoto
authors.forename: N
authors.initials: N
authors.lastname: Yamashita
authors.forename: A
authors.initials: A
authors.lastname: Suda
authors.forename: K
authors.initials: K
authors.lastname: Shimada
authors.forename: H
authors.initials: H
authors.lastname: Nihei
authors.forename: M
authors.initials: M
authors.lastname: Ando
mesh_terms: D000328:Adult; D018798:Anemia, Iron-Deficiency / Q000097:blood* / Q000209:etiology / Q000628:therapy; D004909:Erythrocyte Indices; D004921:Erythropoietin / Q000627:therapeutic use; D005260:Female; D005293:Ferritins / Q000097:blood*; D006454:Hemoglobins / Q000032:analysis*; D006801:Humans; D007676:Kidney Failure, Chronic / Q000097:blood / Q000628:therapy*; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins; D006435:Renal Dialysis / Q000009:adverse effects*; D012156:Reticulocytes / Q000737:chemistry; D014168:Transferrin / Q000032:analysis*
chemical_list: D006454:Hemoglobins; D011994:Recombinant Proteins; D014168:Transferrin; D004921:Erythropoietin; D005293:Ferritins